Dendritic cell vaccine (PrimeVax Immuno-Oncology)

N/A

Report date: 2025/09/12 14:29:56

Base Information

Drug NameDendritic cell vaccine (PrimeVax Immuno-Oncology)

Drug Alias NamePV-001-DC

ClassificationVaccines > Development/production technology > Dendritic cell vaccineCell and gene therapy > Cell therapy > Immune system cell therapy > Dendritic cell therapy > Dendritic cell vaccine

Mechanisms of ActionImmunostimulants

TargetsNot applicable

Therapy Area/IndicationsMelanoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesPrimevax Immuno-Oncology Inc

China Registration ClassN/A

Develop Information

Active CompaniesPrimevax Immuno-Oncology Inc

Inactive CompaniesN/A

Active IndicationsMelanoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A